I am a clinician-scientist with experience in the application of a wide range of molecular imaging tools in both preclinical and clinical settings. At Memorial Sloan Kettering, I direct a laboratory that focuses on the development, characterization, and evaluation of translational silica nanomaterials for cancer applications. We use these materials in conjunction with imaging tools (including PET and optical devices) to individualize patient care. In addition, my team explores the biological and chemical interactions of these materials at multiple spatial scales — from the cellular/molecular level to that of organs and tissues. We then link these findings to sites of disease using whole-body imaging studies of small animal models and humans.
Michelle S. Bradbury, MD, PhD
Director of Intraoperative Imaging, Radiology
Research FocusClinician-scientist Michelle Bradbury develops translational, tumor-targeting, PET-optical silica nanoparticle probes for diagnostics, drug delivery, and sensing.
- PhD – Massachusetts Institute of Technology, Cambridge, MA
- MD – George Washington University, School of Medicine, Washington, DC
- Rosen BR, Belliveau JW, Buchbinder BR, McKinstry RC, Porkka LM, Kennedy DN, Neuder MS, Fisel CR, Aronen HJ, Kwong KK, Weisskoff RM, Cohen MS, and Brady TJ. Contrast agents and cerebral hemodynamics, Magn Reson Med 1991; 19: 001-008.
- Young SW, Sidhu MK, Qing F, Muller HH, Neuder MS, Zanassi G, Mody TD, Hemmi G, Dow W, Mutch JD, Sessler JL, and Miller RA: Preclinical evaluation of gadolinium (III) texaphyrin [Gd-Tex]: A new paramagnetic contrast agent for MR imaging, Invest Rad 1994; 29: 330-8.